



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Risankizumab

Cat. No.:	HY-P99248
CAS No.:	1612838-76-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit ( $K_d < 10$ pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes ( $IC_{50} = 2$ pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis <sup>[1][2][3]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	IL-23 <10 pM ( $K_d$ )	
<b>In Vitro</b>	Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with $K_d$ s <10 pM <sup>[3]</sup> . Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with $IC_{50}$ s of 2 pM and 17 pM, respectively <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days) <sup>[3]</sup>
	Dosage:	1 mg/kg
	Administration:	i.p.; single dosage
	Result:	Significantly inhibited IL23-induced ear swelling and cytokine production.
	Animal Model:	Cynomolgus monkeys <sup>[3]</sup>
	Dosage:	1.0 mg/kg
	Administration:	i.v. or s.c.
	Result:	Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys <sup>[1]</sup> .

	IV (1 mg/kg)	SC (1 mg/kg)
AUC <sub>inf</sub> (μg·day/mL)	202 ± 33.5	142 ± 33.3
CL (mL/day/kg)	5.18 ± 0.8	/
Vd, ss (mL/kg)	88.3 ± 3.12	/
t <sub>1/2</sub> (h)	12.2 ± 2.28/	9.15 ± 1.87
C <sub>max</sub> (μg/mL)	/	10.1 ± 3.14
T <sub>max</sub> (day)	/	2.11 ± 1.84
F (%)	/	70.4 ± 16.5

## REFERENCES

- [1]. McKeage K, Duggan S. Risankizumab: First Global Approval. *Drugs*. 2019 Jun;79(8):893-900.
- [2]. Andrea Chiricozzi, et al. Risankizumab for the treatment of moderate to severe psoriasis. *Expert Opinion on Biological Therapy*. Volume 19, 2019 - Issue 1
- [3]. Singh S, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. *MAbs*. 2015;7(4):778-91.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA